⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13916373 | 0.89 | — | — | |
| SCHEMBL13916488 | 0.80 | — | — | |
| 1,2-Dibromoethane SCHEMBL11411440 | 0.71 | — | — | |
| SCHEMBL13916493 | 0.69 | — | — | |
| Dibromomethane SCHEMBL20701 | 0.68 | — | — | |
| SCHEMBL2289057 | 0.67 | — | — | |
| SCHEMBL3761033 | 0.67 | — | — | |
| N-Propyl Bromide SCHEMBL796551 | 0.63 | — | — | |
| 2-Bromoethanol SCHEMBL13916047 | 0.63 | — | — | |
| 1,2-Dibromoethane SCHEMBL1448860 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4606434-A2 | DEUTERATED DERIVATIVES OF RUXOLITINIB | Sun Pharmaceutical Industries, Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250025467-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20230355629-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20210330674-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | CONCERT PHARMACEUTICALS INC (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3882249-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | CoNCERT Pharmaceuticals, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3450434-B1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | CONCERT PHARMACEUTICALS INC (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20190308976-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | CONCERT PHARMACEUTICALS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20170239254-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | CONCERT PHARMACEUTICALS INC (US) | 2017-08-24 | — | — | US | disclosed |
| US-9249149-B2 | Deuterated derivatives of ruxolitinib | CONCERT PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150239896-A1 | Deuterated Derivatives of Ruxolitinib | SUN PHARMACEUTICAL INDUSTRIES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150197525-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | CONCERT PHARMACEUTICALS, INC. | 2015-07-16 | — | — | US | disclosed |
| EP-2861600-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | Concert Pharmaceuticals Inc. (US) | 2015-04-22 | — | — | EP | disclosed |
| WO-2013188783-A1 | DEUTERATED DERIVATIVES OF RUXOLITINIB | CONCERT PHARMACEUTICALS, INC. (US) | 2013-12-19 | — | — | WO | disclosed |
| US-20120058085-A1 | Deuterium Modified Benzimidazoles | CONCERT PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| US-20080299216-A1 | DEUTERIUM-ENRICHED ARIPIPRAZOLE | PROTIA, LLC (US) | 2008-12-04 | — | — | US | disclosed |